呼吸器感染症およびウイルス性緊急症に対する戦略と治療（STRIVE）：塩野義製薬のプロテアーゼ阻害剤（エンシトレルビル）

基本情報

NCT ID

NCT05605093

ステータス

中止

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

602

治験依頼者名

University of Minnesota

概要

Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization.

対象疾患

介入

依頼者（Sponsor）

実施施設 (3)